The brave new era of human genetic testing
✍ Scribed by Hans-Jürgen Bandelt; Yong-Gang Yao; Martin B. Richards; Antonio Salas
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 144 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0265-9247
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The commercialization of ‘big science’ is in full swing, leading to situations in which the ethical principles of academia are beginning to be compromised. This is exemplified by the profitable business of genetic ancestry testing. The goals of this sort of ‘big science’ are not necessarily in any way novel, however. In particular, large genotyping projects have a certain start‐up time when their design is frozen in, so that the projects often lag behind the development of genetic knowledge. On the other hand, extremely provisional knowledge about potential disease markers is being rapidly turned into questionable ‘tests’, purporting to determine risk factors for complex disorders, by private companies that are eager to get their share of a profitable market of the future. The flow of money generated by such concerns looks likely to erode traditional research operations and small‐scale projects, which risk becoming pebbles on the ‘big science’ landscape. BioEssays 30:1246–1251, 2008. © 2008 Wiley Periodicals, Inc.
📜 SIMILAR VOLUMES
Medicine is undergoing a quiet revolution. Molecular genetics is transforming clinical science and practice; the development of the Human Genome Project allows new methods of disease identification and of predicting disease patterns for individual patients. Knowledge of the human genome will deepen
Recent advances in molecular technologies have resulted in the ability to screen hundreds of thousands of single nucleotide polymorphisms and tens of thousands of gene expression profiles. While these data have the potential to inform investigations into disease etiologies and advance medicine, the